false 0001123494 0001123494 2024-05-14 2024-05-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event Reported): May 14, 2024

 

HARVARD BIOSCIENCE, INC.

(Exact Name of Registrant as Specified in Charter)

   

Delaware 001-33957 04-3306140
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

84 October Hill Road, Holliston, MA 01746

(Address of Principal Executive Offices) (Zip Code)

 

(508) 893-8999

(Registrant's telephone number, including area code)

 

   

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value HBIO The NASDAQ Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

On May 14, 2024, Harvard Bioscience, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders, at which the Company’s stockholders voted on three proposals that are described in detail in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 3, 2024.

 

The voting results for each of the proposals are reported below.

 

Proposal 1 - Election of Director

 

The Company’s stockholders elected one Class III Director for a three-year term, such term to continue until the annual meeting of stockholders in 2027 and until such director’s successor is duly elected and qualified or until his earlier resignation or removal.

 

Name  Votes For  Votes Withheld  Broker Non-Votes
Alan Edrick   19,722,574    10,861,497    4,292,458 

 

 

Proposal 2 –Ratification of the Appointment of Grant Thornton LLP

 

The Company’s stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. There were no broker non-votes on this proposal.

 

Votes For  Votes Against  Votes Abstained
 34,794,995    73,003    8,531 

 

 

Proposal 3 –Approval, by Non-Binding Advisory Vote, of the Compensation of the Named Executive Officers

 

The Company’s stockholders approved the compensation of the Company’s named executive officers, by a non-binding advisory vote:

 

Votes For  Votes Against  Votes Abstained  Broker Non-Votes
 27,472,149    903,608    2,208,314    4,292,458 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  HARVARD BIOSCIENCE, INC.
   
Date: May 14, 2024 /s/ John Fry  
  John Fry  
  Chief Legal Counsel and Secretary

 

 

 

 

 

 

 

 

 

 

 

 

 

 

v3.24.1.1.u2
Cover
May 14, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 14, 2024
Entity File Number 001-33957
Entity Registrant Name HARVARD BIOSCIENCE, INC.
Entity Central Index Key 0001123494
Entity Tax Identification Number 04-3306140
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 84 October Hill Road
Entity Address, City or Town Holliston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01746
City Area Code (508)
Local Phone Number 893-8999
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol HBIO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Harvard Bioscience (NASDAQ:HBIO)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Harvard Bioscience.
Harvard Bioscience (NASDAQ:HBIO)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Harvard Bioscience.